Replies to post #516497 on Anavex Life Sciences Corp (AVXL)

[Hosai]

Donanemab 257 patient phase 2 results with 25% dropout and with their primary endoint iARDS p value 0.04 and secondaries trending in right direction but all with non stat sig scores in ADAS COG, CDR SB, iADL and MMSE, the ARIA safety issues, extra unexplained brain volume loss, no intriguing sub group and no long term data at the time was valued at $22 billion going by implied market moves, but you think Blarcamesine 2b/3 currently worth $350 million?

https://www.nejm.org/doi/full/10.1056/NEJMoa2100708

[Kentucky123]

Thank you for your detailed response. It makes total sense to me. I am happy you are helping people.

[AlchemicalVoyager13]

Doc, first, thanks for all you do for MS patients. In order to run a 1,000 person confirming P3 trial I believe the cost will be more like $300MM. And you are looking three years out....if Missling (really, a new CEO needed) runs it. As such, 100% more shares at current SP, or more, need to be issued but who the heck would buy them given recent turn of events? They need to issue a good 150 million shares. No investor in their right mind will pay more than $2 ish. That is 150% dilution or so. This is at best a crap shot with a new CEO and a write off with Missling at helm.